Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
75
NUVB Quote, Financials, Valuation and Earnings
Last price:
$8.55
Seasonality move
:
-2.71%
Day range:
$8.15 - $8.70
52-week range:
$1.54 - $8.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
108.58x
P/B ratio:
8.99x
Volume:
6.1M
Avg. volume:
10.3M
1-year change:
208.66%
Market cap:
$2.9B
Revenue:
$7.9M
EPS (TTM):
-$0.64
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NUVB
Nuvation Bio, Inc.
|
$6.9M | -$0.15 | 458.48% | -72.75% | $10.25 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$4.2M | -$1.04 | -- | -18.07% | $31.00 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -1.98% | 745.84% | $29.04 |
|
RPID
Rapid Micro Biosystems, Inc.
|
$7.6M | -$0.25 | 36.29% | -4.17% | $8.00 |
|
SPRY
ARS Pharmaceuticals, Inc.
|
$28.7M | -$0.49 | -69.68% | -148.61% | $28.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NUVB
Nuvation Bio, Inc.
|
$8.55 | $10.25 | $2.9B | -- | $0.00 | 0% | 108.58x |
|
CVM
CEL-SCI Corp.
|
$6.45 | $42.50 | $19.6M | -- | $0.00 | 0% | -- |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$16.43 | $31.00 | $830.5M | -- | $0.00 | 0% | 57.00x |
|
PFE
Pfizer Inc.
|
$26.03 | $29.04 | $148B | 15.17x | $0.43 | 6.61% | 2.37x |
|
RPID
Rapid Micro Biosystems, Inc.
|
$3.98 | $8.00 | $176.4M | -- | $0.00 | 0% | 5.78x |
|
SPRY
ARS Pharmaceuticals, Inc.
|
$9.93 | $28.67 | $981.6M | 174.21x | $0.00 | 0% | 6.84x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NUVB
Nuvation Bio, Inc.
|
38.98% | 0.827 | 16.41% | 8.18x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
KALV
KalVista Pharmaceuticals, Inc.
|
94.33% | -1.515 | 45.9% | 6.99x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
RPID
Rapid Micro Biosystems, Inc.
|
35.22% | 3.202 | 16.29% | 2.83x |
|
SPRY
ARS Pharmaceuticals, Inc.
|
39.84% | 0.374 | 9.84% | 6.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NUVB
Nuvation Bio, Inc.
|
$9.2M | -$56.4M | -43.02% | -52.16% | -430.14% | -$60.9M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
KALV
KalVista Pharmaceuticals, Inc.
|
$12.5M | -$46.1M | -97.51% | -243.25% | -336.33% | -$54.8M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
RPID
Rapid Micro Biosystems, Inc.
|
$696K | -$11.4M | -59.49% | -68.33% | -145.09% | -$10M |
|
SPRY
ARS Pharmaceuticals, Inc.
|
$24.3M | -$53.2M | -35.53% | -38.98% | -163.66% | -$47.2M |
Nuvation Bio, Inc. vs. Competitors
-
Which has Higher Returns NUVB or CVM?
CEL-SCI Corp. has a net margin of -425.24% compared to Nuvation Bio, Inc.'s net margin of --. Nuvation Bio, Inc.'s return on equity of -52.16% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital NUVBNuvation Bio, Inc.70.4% -$0.16 $534M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About NUVB or CVM?
Nuvation Bio, Inc. has a consensus price target of $10.25, signalling upside risk potential of 19.88%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Nuvation Bio, Inc., analysts believe CEL-SCI Corp. is more attractive than Nuvation Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NUVBNuvation Bio, Inc.7 0 0 CVMCEL-SCI Corp.1 0 0 -
Is NUVB or CVM More Risky?
Nuvation Bio, Inc. has a beta of 1.580, which suggesting that the stock is 58.01% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock NUVB or CVM?
Nuvation Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvation Bio, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NUVB or CVM?
Nuvation Bio, Inc. quarterly revenues are $13.1M, which are larger than CEL-SCI Corp. quarterly revenues of --. Nuvation Bio, Inc.'s net income of -$55.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Nuvation Bio, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvation Bio, Inc. is 108.58x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NUVBNuvation Bio, Inc.108.58x -- $13.1M -$55.8M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns NUVB or KALV?
KalVista Pharmaceuticals, Inc. has a net margin of -425.24% compared to Nuvation Bio, Inc.'s net margin of -361.39%. Nuvation Bio, Inc.'s return on equity of -52.16% beat KalVista Pharmaceuticals, Inc.'s return on equity of -243.25%.
Company Gross Margin Earnings Per Share Invested Capital NUVBNuvation Bio, Inc.70.4% -$0.16 $534M KALVKalVista Pharmaceuticals, Inc.91% -$0.92 $299.6M -
What do Analysts Say About NUVB or KALV?
Nuvation Bio, Inc. has a consensus price target of $10.25, signalling upside risk potential of 19.88%. On the other hand KalVista Pharmaceuticals, Inc. has an analysts' consensus of $31.00 which suggests that it could grow by 88.68%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Nuvation Bio, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Nuvation Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NUVBNuvation Bio, Inc.7 0 0 KALVKalVista Pharmaceuticals, Inc.7 0 0 -
Is NUVB or KALV More Risky?
Nuvation Bio, Inc. has a beta of 1.580, which suggesting that the stock is 58.01% more volatile than S&P 500. In comparison KalVista Pharmaceuticals, Inc. has a beta of -0.135, suggesting its less volatile than the S&P 500 by 113.476%.
-
Which is a Better Dividend Stock NUVB or KALV?
Nuvation Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KalVista Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvation Bio, Inc. pays -- of its earnings as a dividend. KalVista Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NUVB or KALV?
Nuvation Bio, Inc. quarterly revenues are $13.1M, which are smaller than KalVista Pharmaceuticals, Inc. quarterly revenues of $13.7M. Nuvation Bio, Inc.'s net income of -$55.8M is lower than KalVista Pharmaceuticals, Inc.'s net income of -$49.5M. Notably, Nuvation Bio, Inc.'s price-to-earnings ratio is -- while KalVista Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvation Bio, Inc. is 108.58x versus 57.00x for KalVista Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NUVBNuvation Bio, Inc.108.58x -- $13.1M -$55.8M KALVKalVista Pharmaceuticals, Inc.57.00x -- $13.7M -$49.5M
-
Which has Higher Returns NUVB or PFE?
Pfizer Inc. has a net margin of -425.24% compared to Nuvation Bio, Inc.'s net margin of 21.32%. Nuvation Bio, Inc.'s return on equity of -52.16% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital NUVBNuvation Bio, Inc.70.4% -$0.16 $534M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About NUVB or PFE?
Nuvation Bio, Inc. has a consensus price target of $10.25, signalling upside risk potential of 19.88%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 11.56%. Given that Nuvation Bio, Inc. has higher upside potential than Pfizer Inc., analysts believe Nuvation Bio, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings NUVBNuvation Bio, Inc.7 0 0 PFEPfizer Inc.7 15 1 -
Is NUVB or PFE More Risky?
Nuvation Bio, Inc. has a beta of 1.580, which suggesting that the stock is 58.01% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock NUVB or PFE?
Nuvation Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.61% to investors and pays a quarterly dividend of $0.43 per share. Nuvation Bio, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios NUVB or PFE?
Nuvation Bio, Inc. quarterly revenues are $13.1M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Nuvation Bio, Inc.'s net income of -$55.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Nuvation Bio, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvation Bio, Inc. is 108.58x versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NUVBNuvation Bio, Inc.108.58x -- $13.1M -$55.8M PFEPfizer Inc.2.37x 15.17x $16.7B $3.6B
-
Which has Higher Returns NUVB or RPID?
Rapid Micro Biosystems, Inc. has a net margin of -425.24% compared to Nuvation Bio, Inc.'s net margin of -146.79%. Nuvation Bio, Inc.'s return on equity of -52.16% beat Rapid Micro Biosystems, Inc.'s return on equity of -68.33%.
Company Gross Margin Earnings Per Share Invested Capital NUVBNuvation Bio, Inc.70.4% -$0.16 $534M RPIDRapid Micro Biosystems, Inc.8.88% -$0.26 $68.4M -
What do Analysts Say About NUVB or RPID?
Nuvation Bio, Inc. has a consensus price target of $10.25, signalling upside risk potential of 19.88%. On the other hand Rapid Micro Biosystems, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 101.01%. Given that Rapid Micro Biosystems, Inc. has higher upside potential than Nuvation Bio, Inc., analysts believe Rapid Micro Biosystems, Inc. is more attractive than Nuvation Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NUVBNuvation Bio, Inc.7 0 0 RPIDRapid Micro Biosystems, Inc.4 0 0 -
Is NUVB or RPID More Risky?
Nuvation Bio, Inc. has a beta of 1.580, which suggesting that the stock is 58.01% more volatile than S&P 500. In comparison Rapid Micro Biosystems, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NUVB or RPID?
Nuvation Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rapid Micro Biosystems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvation Bio, Inc. pays -- of its earnings as a dividend. Rapid Micro Biosystems, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NUVB or RPID?
Nuvation Bio, Inc. quarterly revenues are $13.1M, which are larger than Rapid Micro Biosystems, Inc. quarterly revenues of $7.8M. Nuvation Bio, Inc.'s net income of -$55.8M is lower than Rapid Micro Biosystems, Inc.'s net income of -$11.5M. Notably, Nuvation Bio, Inc.'s price-to-earnings ratio is -- while Rapid Micro Biosystems, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvation Bio, Inc. is 108.58x versus 5.78x for Rapid Micro Biosystems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NUVBNuvation Bio, Inc.108.58x -- $13.1M -$55.8M RPIDRapid Micro Biosystems, Inc.5.78x -- $7.8M -$11.5M
-
Which has Higher Returns NUVB or SPRY?
ARS Pharmaceuticals, Inc. has a net margin of -425.24% compared to Nuvation Bio, Inc.'s net margin of -157.38%. Nuvation Bio, Inc.'s return on equity of -52.16% beat ARS Pharmaceuticals, Inc.'s return on equity of -38.98%.
Company Gross Margin Earnings Per Share Invested Capital NUVBNuvation Bio, Inc.70.4% -$0.16 $534M SPRYARS Pharmaceuticals, Inc.74.8% -$0.52 $245.4M -
What do Analysts Say About NUVB or SPRY?
Nuvation Bio, Inc. has a consensus price target of $10.25, signalling upside risk potential of 19.88%. On the other hand ARS Pharmaceuticals, Inc. has an analysts' consensus of $28.67 which suggests that it could grow by 188.69%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than Nuvation Bio, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than Nuvation Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NUVBNuvation Bio, Inc.7 0 0 SPRYARS Pharmaceuticals, Inc.6 0 0 -
Is NUVB or SPRY More Risky?
Nuvation Bio, Inc. has a beta of 1.580, which suggesting that the stock is 58.01% more volatile than S&P 500. In comparison ARS Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NUVB or SPRY?
Nuvation Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ARS Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvation Bio, Inc. pays -- of its earnings as a dividend. ARS Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NUVB or SPRY?
Nuvation Bio, Inc. quarterly revenues are $13.1M, which are smaller than ARS Pharmaceuticals, Inc. quarterly revenues of $32.5M. Nuvation Bio, Inc.'s net income of -$55.8M is lower than ARS Pharmaceuticals, Inc.'s net income of -$51.2M. Notably, Nuvation Bio, Inc.'s price-to-earnings ratio is -- while ARS Pharmaceuticals, Inc.'s PE ratio is 174.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvation Bio, Inc. is 108.58x versus 6.84x for ARS Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NUVBNuvation Bio, Inc.108.58x -- $13.1M -$55.8M SPRYARS Pharmaceuticals, Inc.6.84x 174.21x $32.5M -$51.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
